Physician profile
Elliot Brown
NPI 1285689315
$34,330.82
in general payments reported to CMS, 2019-2025
25 companies · $61.24 in 2025
The $61.24 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,811 · 2021: $256 · 2022: $13K · 2023: $8,292 · 2024: $249 · 2025: $61.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Food and Beverage | $601.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28,667.89 | 2019-2024 | Watchman Access System, Watchman Flx |
| Cvrx, INC. | $3,318.81 | 2022 | |
| Abbott Laboratories | $1,167.85 | 2019-2024 | Cardiomems |
| Medtronic, INC. | $149.45 | 2022 | |
| Biotronik INC. | $147.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $131.38 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $113.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.77 | 2019-2021 | |
| Amarin Pharma, INC. | $56.90 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $56.26 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $56.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $52.16 | 2019 | |
| Abiomed | $42.76 | 2025 | |
| Amgen INC. | $41.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.13 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.84 | 2020 | |
| Merck Sharp & Dohme LLC | $30.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.11 | 2019 | |
| Carestream Dental, LLC | $24.16 | 2020 | |
| United Therapeutics Corporation | $18.48 | 2025 | Tyvaso |
| Pfizer INC. | $15.26 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2022 | |
| Allergan, INC. | $12.46 | 2019 | |
| Medicure Pharma INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.